Tuesday, April 24, 2012

International Stem Cell Corporation Appoints MZ Group as its Investor Relations Firm

International Stem Cell Corporation (OTCBB: ISCO) (www.internationalstemcell.com) today announced it has appointed MZ Group as its investor relations advisor. MZ will assist International Stem Cell with investor relations consulting, corporate communications and investor and shareholder outreach. ISCO also announced the promotion of Dr. Simon Craw to the position of Executive Vice President with responsibility for Business Development and Investor Relations.
"MZ is an excellent investor relations partner for several reasons," said Dr. Andrey Semechkin, Ph.D., Chief Executive Officer of International Stem Cell. "With our recent financing and steady progress in our Lifeline Skin Care and Cell Technology businesses, we have a tremendous opportunity to introduce our company to a wide variety of investors. MZ has access to a large pool of potential investors who may be interested in an emerging life sciences company such as ours.
"We also look forward to steadily expanding our corporate communications efforts with the media and the life sciences industry to further solidify our corporate brands. With this in mind I have promoted Dr. Craw to a new position of EVP, to be responsible for Business Development and oversee our Investor Relations program in addition to his existing responsibly for our Stem Cell banking program. As part of his new role Dr. Craw will work closely with our VP of Research and Development and maintain his involvement in the development of our technologies."
"We see a terrific opportunity to help management achieve their goals and objectives," said Ted Haberfield, Managing Partner of MZ Group North America. "With advanced R&D and manufacturing facilities located in California and Maryland and its patented parthenogenetic stem cell technology to treat human degenerative diseases, the Company is in the advanced stages of developing multiple groundbreaking commercial applications. We believe investors will be extremely excited to learn more about International Stem Cell Corporation."
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

International Stem Cell Corporation
Dr. Simon Craw, Executive Vice President
Phone: 760-940-6383
Email: ir@intlstemcell.com
Investor Relations:
MZ Group
Mark McPartland
Senior Vice President
Phone: 212-301-7130
Email: markmcp@mzgroup.us
Web: www.mz-ir.com
Apr 23, 2012

No comments:

Post a Comment